These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38229349)

  • 21. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
    Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study.
    Connelly K; Kandane-Rathnayake R; Hoi A; Louthrenoo W; Hamijoyo L; Luo SF; Wu YJ; Cho J; Lateef A; Lau CS; Chen YH; Navarra S; Zamora L; Li Z; An Y; Sockalingam S; Hao Y; Zhang Z; Chan M; Katsumata Y; Harigai M; Oon S; Bae SC; O'Neill S; Gibson KA; Basnayake B; Kikuchi J; Takeuchi T; Ng KPL; Tugnet N; Kumar S; Goldblatt F; Law A; Tee M; Tee C; Tanaka Y; Ohkubo N; Tan JY; Karyekar CS; Nikpour M; Golder V; Morand EF
    Arthritis Rheumatol; 2023 Mar; 75(3):401-410. PubMed ID: 36122172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
    de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
    Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial.
    Mucke J; Kuss O; Brinks R; Schanze S; Schneider M
    Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus.
    Smith EMD; Tharmaratnam K; Al-Abadi E; Armon K; Bailey K; Brennan M; Ciurtin C; Gardner-Medwin J; Haslam KE; Hawley D; Leahy A; Leone V; Malik G; McLaren Z; Pilkington C; Ramanan AV; Rangaraj S; Ratcliffe A; Riley P; Sen E; Sridhar A; Wilkinson N; Hedrich CM; Jorgensen A; Beresford MW
    Rheumatology (Oxford); 2022 Aug; 61(8):3378-3389. PubMed ID: 34894234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
    Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
    Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.
    Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Nikpour M; Morand EF;
    Arthritis Res Ther; 2017 Mar; 19(1):62. PubMed ID: 28320433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis.
    Kisaoglu H; Baba O; Kalyoncu M
    Pediatr Nephrol; 2023 Apr; 38(4):1167-1175. PubMed ID: 36156735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.
    Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Lee AL; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Morand EF; Nikpour M;
    Arthritis Res Ther; 2016 Nov; 18(1):260. PubMed ID: 27829463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
    Kandane-Rathnayake R; Louthrenoo W; Hoi A; Luo SF; Wu YJ; Chen YH; Cho J; Lateef A; Hamijoyo L; Navarra SV; Zamora L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Hao Y; Zhang Z; Kikuchi J; Takeuchi T; Basnayake BMDB; Chan M; Ng KPL; Tugnet N; Kumar S; Oon S; Goldblatt F; O'Neill S; Gibson KA; Ohkubo N; Tanaka Y; Bae SC; Lau CS; Nikpour M; Golder V; Morand EF;
    Arthritis Res Ther; 2022 Mar; 24(1):70. PubMed ID: 35287720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.
    Babaoğlu H; Li J; Goldman D; Magder LS; Petri M
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):225-232. PubMed ID: 31507071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
    Fernández M; Calvo-Alén J; Alarcón GS; Roseman JM; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Sanchez ML; Reveille JD
    Arthritis Rheum; 2005 Jun; 52(6):1655-64. PubMed ID: 15934092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE.
    Cody EM; Wilson BE; Ogbu EA; Huggins JL; Chen C; Qiu T; Ting TV; Flores F; Huang B; Brunner HI
    Lupus Sci Med; 2023 May; 10(1):. PubMed ID: 37253553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus.
    Kandane-Rathnayake R; Kent JR; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra SA; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Hoi A; Nikpour M; Morand E
    Lupus; 2019 Dec; 28(14):1669-1677. PubMed ID: 31718467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.